SCHEMBL3886511

SCHEMBL3886511

COc1ccc(OC)c(C(=O)CN2CCC(Cc3ccccc3NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.56
MAPK12 P53778 7/20 0.51
HCK P08631 3/20 0.51
MAPK13 O15264 4/20 0.51
MAPK11 Q15759 4/20 0.51
DDR2 Q16832 2/20 0.51
TNF P01375 2/20 0.51
SRC P12931 2/20 0.51
GSK3B P49841 2/20 0.51
CIT O14578 1/20 0.51
MUSK O15146 1/20 0.51
MAP3K7 O43318 1/20 0.51
RIPK2 O43353 1/20 0.51
STK10 O94804 1/20 0.51
MAP4K4 O95819 1/20 0.51
CHEK2 O96017 1/20 0.51
ABL1 P00519 1/20 0.51
EGFR P00533 1/20 0.51
RAF1 P04049 1/20 0.51
NTRK1 P04629 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879566 0.95 MAPK14 (0.54) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3878634 0.91 MAPK14 (0.56) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3883623 0.90 MAPK14 (0.55) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3879934 0.88 MAPK14 (0.54) MAPK14MAPK12MAPK13MAPK11BRAF
SCHEMBL3883386 0.88 MAPK14 (0.53) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3874599 0.87 MAPK14 (0.55) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3875668 0.87 MAPK14 (0.55) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3881514 0.85 MAPK14 (0.54) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3876207 0.85 MAPK14 (0.52) MAPK14MAPK12HCKMAPK13MAPK11
SCHEMBL3888937 0.84 MAPK14 (0.52) MAPK14MAPK12HCKMAPK13MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541368-B2 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) AVENTIS PHARMACEUTICALS INC. (US) 2009-06-02 US disclosed
US-20060063796-A1 Pyrazoles as inhibitors of tumor necrosis factor AVENTIS PHARMACEUTICALS INC. (US) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063796-A1 Pyrazoles as inhibitors of tumor necrosis factor TNF, LITAF, MAPK1 MAPK14 26/4885MAPK12 50/4885HCK 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.